Last $3.27 USD
Change Today +0.02 / 0.62%
Volume 95.1K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Open
$3.23
Previous Close
$3.25
Day High
$3.32
Day Low
$3.20
52 Week High
01/3/14 - $8.29
52 Week Low
12/12/14 - $3.08
Market Cap
116.9M
Average Volume 10 Days
350.0K
EPS TTM
$-1.84
Shares Outstanding
35.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer immunotherapy product to enhance the destruction of cancer initiating cells; a Phase II ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase II immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its subsidiary, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer
Total Annual Compensation: $190.6K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:30 PM

Neostem, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Douglas W. Losordo, Chief Medical Officer, Robin L. Smith, Executive Chairman and Chief Executive Officer.

Neostem, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM

Neostem, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Robin L. Smith, Executive Chairman and Chief Executive Officer.

Neostem, Inc. - Special Call

To review clinical data from phase 2 PreSERVE AMI Trial

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $3.27 USD +0.02

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.30 USD -0.03
Cesca Therapeutics Inc $1.13 USD +0.04
Cytori Therapeutics Inc $0.48 USD -0.0141
Nuo Therapeutics Inc $0.33 USD -0.0002
Vericel Corp $2.87 USD +0.01
View Industry Companies
 

Industry Analysis

NBS

Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.1x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.